University Hospital Basel
Basel, Canton of Basel-City, 4031, Switzerland
NCT Number: NCT07796945
The aim of this study is to improve the medical care of patients with infections for which the cause cannot be clearly identified as bacterial or viral. To achieve this, we are investigating a new inflammatory marker in the blood that may help identify severe bacterial infections more quickly. Early detection is important to prevent complications and ensure that patients receive the most appropriate treatment as soon as possible.
This is an observational study. The knowledge gained from this study may help improve the care of patients with infections of unclear origin by supporting faster diagnosis, earlier treatment, improved risk assessment, and better planning of follow-up care.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Basel, Canton of Basel-City, 4031, Switzerland
This observational study evaluates the diagnostic and prognostic value of Human Neutrophil Lipocalin (HNL) in patients presenting to the Emergency Department (ED) with suspected infection.
Early identification of bacterial infection and sepsis remains a major challenge in emergency care due to the heterogeneity of clinical presentations and the lack of highly accurate diagnostic tools. In particular, distinguishing patients at low risk from those at risk of clinical deterioration is crucial for appropriate treatment decisions, triage, and disposition planning. Delayed recognition of bacterial infection and sepsis is associated with adverse outcomes, especially in patients with atypical presentations.
HNL has emerged as a promising biomarker for differentiating bacterial from viral infections. Previous studies have demonstrated a high diagnostic accuracy of HNL, with reported sensitivity and specificity exceeding 90%, potentially outperforming routinely used biomarkers such as white blood cell count (WBC) and C-reactive protein (CRP). A rapid and reliable biomarker for identifying bacterial infection could support earlier diagnosis, optimize patient management, reduce progression to sepsis, and contribute to more appropriate antibiotic use.
The primary objective of this study is to assess the diagnostic performance of HNL for the detection of bacterial infection in ED patients and to compare its accuracy with routinely used biomarkers, including WBC, CRP, and procalcitonin (PCT).
Secondary objectives include: Comparing the diagnostic performance of HNL measured in serum versus activated Li-heparin whole blood. Evaluating factors that may influence the predictive value of HNL, including age, sex, comorbidities, immunosuppression, and antibiotic treatment. Assessing the prognostic value of HNL for 30-day mortality and comparing its performance with serum lactate, an established predictor of adverse outcomes.
The results of this study may contribute to improved risk stratification and clinical decision-making in patients presenting to the ED with suspected infection.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline blood sample; diagnosis adjudicated after completion of follow-up (up to 30 days)
Diagnostic performance of HNL, WBC, CRP and PCT measured in venous blood samples collected at Emergency Department screening for identifying bacterial infection. Final infection classification (bacterial, viral, other infection, or no infection) will be determined by an independent adjudication committee based on clinical records, laboratory results and microbiological findings.
Time frame: Baseline blood sample; diagnosis adjudicated after completion of follow-up (up to 30 days)
Sensitivity of HNL, WBC, CRP and PCT for identifying bacterial infection using the adjudicated infection diagnosis as the reference standard.
Time frame: Baseline blood sample; diagnosis adjudicated after completion of follow-up (up to 30 days)
Specificity of HNL, WBC, CRP and PCT for identifying sepsis and septic shock using adjudicated Sepsis-3 diagnoses as the reference standard.
Time frame: 30 days after enrolment
Death from any cause within 30 days after enrolment, assessed through follow-up contact with the patient's general practitioner, the patient or a relative, or other available sources.
Time frame: 30 days after enrolment
Cause of death among participants who die during the 30-day follow-up period.
Time frame: 30 days after enrolment
Re-presentation to hospital occurring within 30 days after enrolment.
Time frame: From hospital admission to discharge, assessed up to 30 days after enrolment
Length of hospital stay for the index presentation, measured in days from admission to discharge.
Time frame: Baseline (at Emergency Department presentation)
MEDS score calculated from baseline clinical variables and patient characteristics obtained at Emergency Department presentation.
Time frame: Baseline (at Emergency Department presentation)
SOFA score calculated from baseline clinical and laboratory variables to assess organ dysfunction.
Time frame: Baseline (at Emergency Department presentation)
qSOFA score calculated from baseline clinical variables to assess the risk of poor outcomes in patients with suspected infection.
University Hospital, Basel, Switzerland
Other
HNL as an Aid in the Diagnosis of Bacterial Infection in the Emergency Department Basel Early Diagnosis of Sepsis (BEDS)
Acronym: BEDS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06178822
Bacterial Infections, Bacterial Infections and Mycoses
Almere Stad, Flevoland, Netherlands
View Trial DetailsNCT07598006
Infections, Inflammation
Nice, Alpes Maritimes, France
View Trial DetailsNCT06548841
Bacterial Infections, Bacterial Infections and Mycoses
Bologna, Italy
View Trial DetailsNCT06149494
COPD, COPD Exacerbation Acute
London, United Kingdom
View Trial Details